“Progress with targeted agents in cholangiocarcinoma – reality or myth?”
At the ESMO1 17th World Congress on Gastrointestinal Cancer held in Barcelona in July 2015, Professor Juan Valle, consultant and medical oncologist at The Christie, Manchester UK, and one of AMMF’s medical advisors, spoke about the progress being made in the understanding of cholangiocarcinoma, the studies being carried out to find target agents, and also genomic profiling, in the search for better and more effective treatments.
Professor Juan Valle’s presentation, “Progress with targeted agents in cholangiocarcinoma – reality or myth?”
Although this is an academic presentation, it does give a very full and understandable overview of current studies on the molecular background of biliary tract cancer, genomic profiling and the alterations that can be seen within the disease.
To view the presentation, click here
In his summary, Professor Valle explained the need for future clinical trials to work with subgroups of patients, as the advances being made by applying genomic technology are now allowing identification of the differences within the disease, and that collaboration on clinical trials are needed in order to find new treatments for biliary tract cancers.
1 The European Society for Medical Oncology
August 2015
